NEW YORK ( TheStreet) -- It's now been two full quarters since healthcare conglomerate Abbott Laboratories ( ABT) effectively separated itself from its drug business -- spinning off that segment into a new entity called AbbVie ( ABBV).The spin-off, which was originally announced in late 2011, was a long-anticipated move, for which Abbott investors cheered. It came with plenty of expectations that the remaining portion of Abbott, which consists of the devices business, would post stronger growth results. But since the separation took effect in January of this year, questions have been raised as to which of the two companies presents the better value. Shares of AbbVie, which have soared more than 30% on the year, have been one of the best performers within the sector. Abbott, meanwhile, has posted gains of 16%. It's not a terrible performance, but the stock has lagged behind Johnson & Johnson ( JNJ) and Medtronic ( MDT). Although second-quarter earnings results were better than expected, I didn't see enough to buy shares of Abbott today with my own money.